Tiquizium (bromide)

• Description:

  Tiquizium bromide is an orally active, atropine-type, nonselective muscarinic antagonist and novel spasmolytic agent. Tiquizium bromide inhibits the developments of gastric lesions and duodenal lesions. Tiquizium bromide induces the mydoriasis and inhibits the Pilocarpine (HY-B0726A) -induced salivation[1][2].

• Product Name Alternative:

  HSR-902

• UNSPSC:

  12352005

• Target:

  MAChR

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Field of Research:

  Neurological Disease; Inflammation/Immunology

• Smiles:

  C[N@@+]12C/C(CC[C@@]1([H])CCCC2)=C(C3=CC=CS3)\C4=CC=CS4.[Br-]

• Molecular Formula:

  C19H24BrNS2

• Molecular Weight:

  410.43

• References & Citations:

  [1]Oshita M, et al. Studies on the affinity and selectivity of tiquizium bromide (HSR-902), a novel spasmolytic agent, for muscarinic receptors. Jpn J Pharmacol. 1987 Jun;44 (2) :222-4. |[2]Morikawa K, et al. [Evaluation of tiquizium bromide (HSR-902) as an antiulcer agent]. Nihon Yakurigaku Zasshi. 1987 Nov;90 (5) :273-83. Japanese.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [71731-58-3]